To overcome the limitations of chimeric antigen receptor (CAR) T cell therapy, Capstan Therapeutics introduced a strategy using targeted lipid nanoparticles (tLNPs) to deliver mRNA to specific T cell subsets, enabling the safe and preferential generation of CAR T cells directly in vivo. L829-LNP showed reduced functional delivery to the liver, efficient delivery of mRNA to target immune cells, improved biodegradability, reduced reactogenicity, and improved tolerability. L829 was rapidly cleared from the liver in CD5-L829-tLNP–treated mice, whereas ALC-0315 levels remained elevated for at least 7 days.
Lipid A-11
N-1039
Lipid A-11 (CICL-1, L829)
To overcome the limitations of chimeric antigen receptor (CAR) T cell therapy, Capstan Therapeutics introduced a strategy using targeted lipid nanoparticles (tLNPs) to deliver mRNA to specific T cell subsets, enabling the safe and preferential generation of CAR T cells directly in vivo. [Read More...]
